



Making Therapies that Make a Difference

CORPORATE UPDATE

JULY 8, 2020

NYSE: ZYME

www.zymeworks.com

Legal Disclaimer

This presentation includes “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of Canadian securities laws, or collectively, forward looking statements. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenue or performance, capital expenditures, financing needs and other information that is not historical information. Forward-looking statements can often be identified by the use of terminology such as “subject to,” “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar expressions, or by discussions of strategy. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of risks and uncertainties, including those described in the "Risk Factors" and other sections of our public filings with the Securities and Exchange Commission and Canadian securities regulators.

These forward-looking statements are made only as of the date hereof, and Zymeworks Inc. undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Dual-Drug Approach to Address HER2-Expressing Cancer Spectrum

Foundational



Zanidatamab (ZW25)

Bispecific HER2 Antibody

- Multiple MOAs to eliminate HER2 signaling
- Combines well with SOC for early lines of therapy
- Cytotoxin-free approach for fragile patients

Transformative




ZW49

Bispecific HER2 Antibody-Drug Conjugate

- Uses HER2 expression to deliver cytotoxin
- Later-stage and/or lower HER2-expressing tumors
- Broad therapeutic window in preclinical studies

Biliary Tract Cancers: Single Agent Zanidatamab Anti-Tumor Activity


Data supports the initiation of a registration-enabling trial in 2L biliary tract cancers



T = Trastuzumab | Data snapshot from unlocked database 30 May 2020 and subject to change.


GEA: Single Agent Zanidatamab Anti-Tumor Activity

Median 3 prior systemic regimens, including prior trastuzumab in most patients




GEA: Addition of Chemo to Zanidatamab Increases Response

Promising activity seen in patients with FISH+ and FISH- disease



T = Trastuzumab | Data snapshot from unlocked database 30 May 2020 and subject to change.

Zanidatamab Clinical Development – Priority Studies



Partnership Updates



Licenses to Azymetric™ and EFECT™ Platforms

- Merck to develop up to 6 multispecific candidates in total, 3 in human health and 3 in animal health
- Financials for 3 Human Health programs:
 - Undisclosed upfront payment
 - **\$411 million**: option exercise fees and clinical development and regulatory approval milestones
 - **\$480 million**: commercial milestones
 - Tiered royalties on worldwide sales
- Financials for 3 Animal Health programs:
 - Undisclosed milestones and tiered royalties

All values in \$USD

Addition of EFECT™ Platform to Collaboration and Extension of Research Term

- BMS gained access to the EFECT™ platform for generating effector silenced Azymetric™ antibodies
- Research term using the Azymetric™ platform extended for Bristol-Myers Squibb (formerly Celgene) to continue development of up to 10 therapeutic candidates
- Financial Summary:
 - **\$12 million** fee
 - Program-specific milestones remain unchanged, totaling **\$1.7 billion** plus single-digit royalties for the 10 potential programs under this collaboration

Summary and Upcoming Catalysts



Zanidatamab Clinical Development – Priority Studies

